Literature DB >> 12791217

Conjunctival allergen challenge: models in the investigation of ocular allergy.

Mark B Abelson1, Oliver Loeffler.   

Abstract

Recently, the number of agents to treat ocular allergy has increased dramatically, from three (pheniramine, antazoline, cromolyn) to more than a dozen. A general increase in the incidence of atopy in recent years and the fact that patients are becoming less tolerant of bothersome signs and symptoms have been driving forces in this increase. As visual tasking, such as reading and working on a computer, has become more prevalent, there is an increased awareness of ocular allergy and the impact it has on quality of life and productivity at work and school. With the need for more effective medications, the development of models, such as the conjunctival allergen challenge (CAC), has made the identification of new agents more efficient. In this article, we review the relevant background on the science behind allergen challenges in the eye, how models are designed, and how models are used in the field today.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791217     DOI: 10.1007/s11882-003-0100-z

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  26 in total

1.  Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.

Authors:  Mark B Abelson; Gregg J Berdy; Thomas Mundorf; Lawrence D Amdahl; Adrienne L Graves
Journal:  J Ocul Pharmacol Ther       Date:  2002-10       Impact factor: 2.671

2.  Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen.

Authors:  D Proud; J Sweet; P Stein; R A Settipane; A Kagey-Sobotka; M H Friedlaender; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  1990-05       Impact factor: 10.793

3.  Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.

Authors:  Peter A D'Arienzo; Andrea Leonardi; George Bensch
Journal:  Clin Ther       Date:  2002-03       Impact factor: 3.393

4.  A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.

Authors:  G J Berdy; D L Spangler; G Bensch; S S Berdy; R C Brusatti
Journal:  Clin Ther       Date:  2000-07       Impact factor: 3.393

5.  Effects of ocular decongestants.

Authors:  M B Abelson; G K Yamamoto; M R Allansmith
Journal:  Arch Ophthalmol       Date:  1980-05

6.  Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis.

Authors:  M B Abelson; W A Chambers; L M Smith
Journal:  Arch Ophthalmol       Date:  1990-01

7.  Inflammatory changes in conjunctival scrapings after allergen provocation in humans.

Authors:  S Bonini; S Bonini; A Vecchione; D M Naim; M R Allansmith; F Balsano
Journal:  J Allergy Clin Immunol       Date:  1988-09       Impact factor: 10.793

8.  Conjunctival eosinophils in allergic ocular disease.

Authors:  M B Abelson; N Madiwale; J H Weston
Journal:  Arch Ophthalmol       Date:  1983-04

9.  Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration.

Authors:  D F Anderson; J D MacLeod; S M Baddeley; A S Bacon; J I McGill; S T Holgate; W R Roche
Journal:  Clin Exp Allergy       Date:  1997-09       Impact factor: 5.018

10.  A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model.

Authors:  H Jerome Crampton
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

View more
  12 in total

1.  Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles.

Authors:  Aude Pauly; Françoise Brignole-Baudouin; Jean-Marc Guenoun; Luisa Riancho; Patrice Rat; Jean-Michel Warnet; Christophe Baudouin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-10       Impact factor: 3.117

2.  Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%.

Authors:  Jack V Greiner; Kimberly Edwards-Swanson; Avner Ingerman
Journal:  Clin Ophthalmol       Date:  2011-01-13

3.  Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.

Authors:  Gail Torkildsen; Abhijit Narvekar; Mark Bergmann
Journal:  Clin Ophthalmol       Date:  2015-09-14

Review 4.  Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis.

Authors:  DeGaulle I Chigbu; Alissa M Coyne
Journal:  Clin Ophthalmol       Date:  2015-07-08

5.  Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%.

Authors:  Mark T Bergmann; Jon I Williams; Paul J Gomes
Journal:  Clin Ophthalmol       Date:  2014-08-13

6.  Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials.

Authors:  Eugene B McLaurin; Nicholas P Marsico; Stacey L Ackerman; Joseph B Ciolino; Julia M Williams; Linda Villanueva; David A Hollander
Journal:  Adv Ther       Date:  2014-09-27       Impact factor: 3.845

7.  Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference.

Authors:  Craig F McCabe; Shannon E McCabe
Journal:  Clin Ophthalmol       Date:  2012-10-29

8.  Automated grading system for evaluation of ocular redness associated with dry eye.

Authors:  John D Rodriguez; Patrick R Johnston; George W Ousler; Lisa M Smith; Mark B Abelson
Journal:  Clin Ophthalmol       Date:  2013-06-20

9.  Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy.

Authors:  Paulo J Gomes; George W Ousler; Donna L Welch; Lisa M Smith; Jeffrey Coderre; Mark B Abelson
Journal:  Clin Ophthalmol       Date:  2013-01-20

Review 10.  Ocular allergy treatment comparisons: azelastine and olopatadine.

Authors:  Leonard Bielory; Praveen Buddiga; Stephen Bigelson
Journal:  Curr Allergy Asthma Rep       Date:  2004-07       Impact factor: 4.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.